What Montair Treats: Main Uses and Benefits

Montair (Montelukast) is generally used across three main therapeutic domains. It is commonly used as a daily, long-term treatment to help manage the symptoms of chronic asthma, provides prophylactic support against exercise-induced bronchoconstriction, and is relevant for easing symptoms associated with seasonal and perennial allergic rhinitis.

This supportive therapeutic benefit focuses on addressing symptoms related to inflammatory or irritative states, such as wheezing, chest tightness, coughing, nasal congestion, and sneezing. It contributes to easing the overall symptom load, which may help support a greater sense of breathing comfort and provides support that helps ease the symptom burden across relevant patient groups.

When used as a preventative measure before physical activity, this application may assist with managing symptoms associated with physical exertion that create noticeable physiological strain, and may support general well-being and functional stability during physical effort. Similarly, for allergies, it helps address symptom clusters that interfere with daily functioning, contributing to improved day-to-day comfort during symptomatic periods. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Respiratory Symptoms

Therapeutic Focus	Primary Symptom Axes Addressed
Asthma Maintenance	Symptoms related to physical discomfort and functional stress (wheezing, chest tightness).
Exercise Prophylaxis	Symptoms associated with acute or episodic changes triggered by exertion.
Allergy Management	Symptoms related to inflammatory or irritative states (congestion, sneezing, runny nose).

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Montair?

This section outlines the official, label-based eligibility requirements for Montair (Montelukast).

---

Eligibility Scope

Classification	Rule Summary (Based on Regulatory Documents)
Contraindicated	Patients with a known hypersensitivity to Montelukast or any of the product's components.
Not Indicated	Acute asthma attacks or status asthmaticus (Montair is for chronic, prophylactic use only).
Conditional Use	Use during pregnancy and lactation is permitted only if clearly essential due to limited safety data.

---

Age-Related Eligibility Rules

Eligibility for children is specific to the condition being treated:

• Asthma: Approved for patients 12 months of age and older.
• Exercise-Induced Bronchoconstriction (EIB): Approved for patients 6 years of age and older.
• Allergic Rhinitis: Approved for Seasonal AR in patients 2 years of age and older, and Perennial AR in patients 6 months of age and older.
• Use Not Established: Safety and efficacy are not established for EIB prevention in children under 6 years or for asthma in children under 12 months.

Condition-Specific Considerations

Patients with severe hepatic impairment have not been assessed for safety and effectiveness. No dosage adjustment is required for patients with renal impairment or mild-to-moderate hepatic impairment. For patients with Phenylketonuria (PKU), the chewable tablets contain phenylalanine.

Interactions with other medicines and products

Official regulatory information addresses interactions involving the metabolism of Montelukast and specific co-administered substances, as well as necessary patient management constraints.

Documented Exposure-Altering Interactions

Montelukast is metabolized by certain liver enzymes (CYP2C8, 2C9, and 3A4). Co-administration with enzyme-modifying medicinal products can alter Montelukast's systemic exposure (AUC).

Interacting Substance	Official Exposure Outcome
Gemfibrozil (Enzyme Inhibitor)	Increases Montelukast systemic exposure (AUC) by approximately 4.4-fold.
Phenobarbital (Enzyme Inducer)	Decreases Montelukast systemic exposure (AUC) by approximately 40%.

Clinical monitoring is considered appropriate when potent enzyme inducers like Rifampicin are co-administered. However, regulatory documents indicate that Montelukast had no clinically important effects on the pharmacokinetics of Theophylline, Warfarin, Prednisone, or oral contraceptives.

Administration and Therapeutic Constraints

Montelukast is not a substitute for oral or inhaled corticosteroids; it must not be abruptly substituted for these medicinal products. Patients with known aspirin sensitivity must continue avoidance of aspirin or non-steroidal anti-inflammatory agents, as Montelukast does not modify the bronchoconstrictor response to these substances. Furthermore, the maximum plasma concentration of the oral granules may be decreased by 35% when co-administered with a high-fat meal.

Montair's mechanism of action is defined by influencing signaling mediated by the cysteinyl leukotriene pathway in the respiratory system. The molecule is classified as a selective Leukotriene Receptor Antagonist that operates by blocking the Cysteinyl Leukotriene Receptor Type 1 (CysLT1).

Molecular Action and Pathway Interruption

Montelukast binds with high affinity to the CysLT1 receptor, preventing endogenous inflammatory chemicals, particularly Leukotriene LTD4, from causing receptor activation. This molecular action suppresses the signal transmission of the Eicosanoid Pathway, which is associated with physiological responses in the airways. This interruption contributes to the molecule's profile as a sustained pathway modulator.

️ Physiological Consequences in Airway Tissue

By blocking the CysLT1 receptors on target cells, the mechanism limits several downstream physiological consequences. This directly prevents receptor activation responsible for smooth muscle contraction (tightening) and decreases the signal leading to vascular permeability, which results in reduced fluid accumulation and swelling in the airway lining. The mechanism thus contributes to maintaining the inhibition of receptor activation, which influences the dynamics of the targeted pathways.

How to Use Montair: Official Administration Guidelines

Montair (montelukast) is administered via the oral route for long-term management, with specific dosing regimens defined by a patient’s age group and the treated condition.

Standard Dosing and Administration

The primary use pattern is once-daily dosing for chronic, continuous treatment. The medicine is available in several official strengths and forms:

Age Group	Standard Once-Daily Dose	Forms
Adults and Adolescents (Age ge 15)	10 mg	Film-Coated Tablet
Pediatric Patients (Age 6 to 14)	5 mg	Chewable Tablet
Pediatric Patients (Age 6 months to 5 years)	4 mg	Chewable Tablet, Oral Granules

For maintenance treatment of asthma, the daily dose should be taken in the evening. If the drug is used solely for allergic rhinitis, administration may occur in the morning or evening. When the drug is used to manage both conditions, the single daily dose should be taken in the evening.

Contextual and Procedural Instructions

Exercise-Induced Bronchoconstriction (EIB) Prophylaxis requires a specific administration schedule: a single dose must be taken at least 2 hours before exercise. A patient already receiving a daily dose for chronic use should not take a second, additional dose for EIB prophylaxis within a 24-hour period. Standard and chewable tablets may be taken with or without food.

Oral Granules must be administered within 15 minutes of opening the packet. The granules can be mixed with a spoonful of soft foods such as applesauce, rice, or ice cream, or with baby formula or breast milk. Granules must never be dissolved in other liquids or stored for later use after mixing.

If a dose is missed, patients are instructed to resume the schedule with the next dose at the regular time and should not take a double dose to compensate.

Research Evidence: Overview of Studies for Montair (Montelukast)

Evidence for Use in Chronic Asthma Maintenance

Research explored how symptoms evolved in groups receiving Montair over time in populations with asthma, a condition characterized by fluctuating or episodic manifestations. The evidence base includes Randomized Controlled Trials (RCTs) that compared Montair to a placebo or to standard inhaled controller therapies, like inhaled corticosteroids (ICS). These studies monitored key physiological measures, such as objective lung function tests, alongside patient-reported outcomes describing perceived discomfort.

Studies described patterns observed in the research related to outcomes linked to inflammatory or irritative states. In the observed populations, Montair was observed in trials exploring how symptoms change over time. In trials comparing Montair to inhaled corticosteroids, the ICS groups often described different patterns in objective lung function measures.

There are limitations regarding the certainty in the research. Comparative evidence is lacking in large-scale studies that track outcomes over many years. Furthermore, data for certain groups remain insufficient because the majority of studies focused on individuals with mild to moderate persistent asthma.

---

Evidence for Use in Acute Prevention of Exercise-Induced Bronchoconstriction (EIB)

Research was studied for its role in addressing outcomes related to acute or episodic changes triggered by physical exertion. The study designs used here were specialized, involving short-term, controlled trials where participants were observed before undertaking a standardized, laboratory-based exercise challenge. Studies monitored the immediate physiological response and tracked how long any temporary physiological imbalance persisted after the exercise.

What remains uncertain is how consistently the observed patterns in controlled laboratory challenge settings translate to real-world physical activities, which are generally more varied. The results apply only to the populations studied, which were largely adults and children over the age of six with diagnosed EIB.

---

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Montair was evaluated in trials exploring outcomes linked to inflammatory or irritative states characteristic of both seasonal and year-round allergies. The research involved randomized trials where Montair was compared to a placebo or to other available allergy treatments. Researchers examined changes in detailed patient-reported outcomes describing perceived discomfort using symptom scoring systems.

Comparative evidence is lacking to firmly establish Montair's standing against common first-line allergy treatments. Consequently, the use of Montair for allergic rhinitis may be positioned in clinical contexts for patients who may not have responded sufficiently to or cannot tolerate other therapies.

Key Studies & References

1. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis (Compares Montelukast efficacy to ICS in children/adolescents)
2. Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis (Compares Montelukast, OAH, and Combination Therapy)
3. Study Details | NCT00090142 | Montelukast in Exercise-Induced Bronchospasm - 2004 (RCT on single dose EIB prevention)
4. Clinical Practice Guideline: Allergic Rhinitis (Context for treatment comparisons)

Common questions about Montair (FAQ)

Q: How long does it take for Montair to start working after I take the first pill?

According to official product information, Montelukast is absorbed rapidly after taking a dose by mouth. The maximum concentration of the medication in the blood is typically reached within 3 to 4 hours.

Q: Can Montair cure my asthma completely?

Regulatory documents indicate that Montelukast is used for the long-term management and control of asthma and allergic rhinitis symptoms. This medicine is considered a maintenance treatment and is not a cure for these chronic conditions.

Q: Can I take Montair if I'm pregnant?

Official labeling states that the medicine may be used during pregnancy only if its use is considered clearly essential.

Q: What is the full list of ingredients in the chewable tablet besides the active ingredient?

The chewable tablets contain the active ingredient, Montelukast sodium, along with several inactive ingredients (excipients). These include mannitol, microcrystalline cellulose, hydroxypropyl cellulose, red ferric oxide, croscarmellose sodium, a flavoring agent (cherry or orange), aspartame, and magnesium stearate.

Q: I have severe liver problems, do I need a dose adjustment?

Regulatory documents indicate that no dose adjustment is suggested for patients with mild-to-moderate liver impairment. However, the pharmacokinetics of the drug have not been studied in patients with severe hepatic impairment.

Q: Is Montair available as a generic drug?

Yes, the active ingredient in Montair, which is montelukast sodium, is widely available as a generic prescription medication from various manufacturers.

Q: Is Montair safe for my 4-year-old with asthma?

Official labeling indicates that Montelukast is approved for the treatment of asthma in pediatric patients 12 months of age and older. The official labeling specifies the appropriate dose form and strength for children in the 2-to-5-year age group.

Q: Where exactly does the Montelukast bind in the body?

Montelukast works by binding to and blocking the Cysteinyl Leukotriene Receptor Type 1 (CysLT1). This receptor is primarily found in the human airway on cells such as airway smooth muscle and other pro-inflammatory cells.

Q: How does Montair work to open up my airways?

The mechanism of action involves blocking the activity of the CysLT1 receptor. This action reduces the negative effects of specific inflammatory chemicals (leukotrienes), which helps to minimize the inflammation, narrowing, and swelling within the airways.

How to Store and Dispose of Montair (Montelukast)

Montair (montelukast) must be stored in specific environmental conditions to maintain its stability, as defined in official regulatory labeling.

Official Storage Requirements

Storage Category	Requirement
Temperature	Store below 25 C (77 F).
Protection	Keep in the original package to protect from light and moisture.
Safety	Must be stored out of the sight and reach of children.

Specific Handling and Disposal

Montelukast oral granules must be administered within 15 minutes of opening the sachet or mixing with food/liquid; the mixture must not be stored for later use. Any unused or expired product, including leftover mixed granules, must be disposed of in accordance with local requirements for pharmaceutical waste.